Nutramax Laboratories Inc v. Synergylabs LLC

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Nutramax Laboratories, Inc. and Nutramax Laboratories Veterinary Sciences, Inc. (South Carolina)
  • Defendant: SynergyLabs, LLC (Florida)
  • Plaintiff's Counsel: Lashgoldberg; Alston & Bird LLP
• Case Identification: 0:26-cv-60930, S.D. Fla., 04/02/2026
• Venue Allegations: Venue is alleged to be proper in the Southern District of Florida because the Defendant resides in the district, based on its state of incorporation and principal place of business.
• Core Dispute: Plaintiff alleges that Defendant's "Wuffes Calming Chews" infringe patents related to synergistic compositions of ingredients used for treating anxiety in mammals.
• Technical Context: The technology resides in the field of animal health supplements, specifically oral compositions formulated to manage stress and anxiety in companion animals like dogs and cats.
• Key Procedural History: The complaint states that Plaintiff's counsel sent a notice letter to Defendant on February 27, 2026, asserting infringement of the patents-in-suit. Subsequent correspondence occurred in which Defendant allegedly did not dispute its role as the manufacturer of the accused products, leading to the filing of this complaint.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,335,384 - "Compositions Comprising Magnolia, Phellodendron, Theanine and/or Whey Protein"

The Invention Explained

• Problem Addressed: The patent's background describes how anxiety, fear, and stress contribute to significant behavioral disorders in companion animals, which can lead to property damage, aggression, or abandonment of the pet Compl. ¶1 '384 Patent, col. 1:19-35 It also notes that conventional pharmaceutical treatments can cause undesirable side effects such as sedation and lethargy '384 Patent, col. 2:45-57
• The Patented Solution: The patent discloses an "anxiolytic composition" that provides a "multimodal approach" by using a synergistic combination of natural ingredients: L-theanine, a whey protein, an extract of magnolia, and an extract of phellodendron '384 Patent, abstract '384 Patent, col. 5:1-7 This combination is intended to manage anxiety by acting on multiple neurotransmitters, such as GABA and serotonin, without causing extreme lethargy '384 Patent, col. 3:23-28 '384 Patent, col. 5:8-11
• Technical Importance: The invention provided a composition based on natural products as an alternative to synthetic pharmaceuticals, addressing a market interest in non-sedating, natural options for managing animal anxiety '384 Patent, col. 3:11-20

Key Claims at a Glance

• The complaint asserts independent claim 1 and dependent claims 3-7 and 9-11 Compl. ¶58
• Independent Claim 1 requires:
  • An anxiolytic composition, comprising a combination of
  • L-theanine,
  • a whey protein,
  • an extract of magnolia, and
  • an extract of phellodendron
  • provided in amounts synergistically effective to modulate one or more neurotransmitters.
• The complaint reserves the right to assert additional claims Compl. ¶61

U.S. Patent No. 12,194,011 - "Compositions Comprising Theanine, Magnolia, and Phellodendron"

The Invention Explained

• Problem Addressed: The '011 Patent, which shares a specification with the '384 Patent, addresses the same problem of anxiety-related behavioral disorders in animals and the shortcomings of existing synthetic drug treatments '011 Patent, col. 1:26-35 '011 Patent, col. 2:50-60
• The Patented Solution: This patent claims an anxiolytic composition based on a synergistic combination of L-theanine with extracts of magnolia and phellodendron '011 Patent, abstract Unlike the independent claims of the '384 Patent, the independent claims of the '011 Patent do not require the presence of a whey protein, focusing instead on the synergy between the amino acid and the two botanical extracts.
• Technical Importance: The invention protects a core combination of ingredients, potentially covering formulations that do not include a whey protein component while still achieving a synergistic anxiolytic effect.

Key Claims at a Glance

• The complaint asserts independent claims 1 and 13 and dependent claims 2-10 and 14-20 Compl. ¶65
• Independent Claim 1 requires:
  • An anxiolytic composition, comprising a combination of
  • L-theanine,
  • at least one of magnolia and an extract of magnolia, and
  • at least one of phellodendron and an extract of phellodendron
  • in amounts synergistically effective to modulate one or more neurotransmitters.
• The complaint reserves the right to assert additional claims Compl. ¶68

III. The Accused Instrumentality

Product Identification

The accused products are the "Wuffes Calming Chews" Compl. ¶3

Functionality and Market Context

The Wuffes Calming Chews are supplements for dogs marketed to alleviate stress and anxiety Compl. ¶3 The complaint alleges that each chew contains 35 mg of L-Theanine, 75 mg of Relora® (described as a blend of magnolia and phellodendron extracts), and dried whey, which is alleged to include a whey protein Compl. ¶33 The complaint further alleges that SynergyLabs is a contract manufacturer that produces the accused products for its client, Wuffes Compl. ¶30 A screenshot from the Wuffes website shows its founder in a manufacturing facility wearing a lab coat with a logo alleged to be that of Defendant SynergyLabs Compl. p. 10 Plaintiff also alleges that Wuffes' marketing equates the formulation of the accused product to Plaintiff's own Solliquin® product and relies on a study of Solliquin® to substantiate its efficacy claims Compl. ¶¶34-35

IV. Analysis of Infringement Allegations

The complaint references claim chart exhibits that were not attached to the publicly filed document. The following tables summarize the infringement allegations based on the narrative in the complaint.

U.S. Patent No. 10,335,384 Infringement Allegations

• Identified Points of Contention:
  • Scope Questions: A potential issue is whether the "dried whey" alleged to be in the accused product meets the "whey protein" limitation of Claim 1. The complaint's "on information and belief" phrasing suggests this may require factual development Compl. ¶33
  • Technical Questions: The "synergistically effective" limitation is functional. A key question will be whether the specific formulation in the accused product can be proven to achieve a synergistic-rather than merely additive-effect on neurotransmitters as claimed. The complaint's argument relies heavily on interpreting the defendant's marketing claims (Compl. ¶¶38; Compl. ¶42).

U.S. Patent No. 12,194,011 Infringement Allegations

• Identified Points of Contention:
  • Scope Questions: The construction of "at least one of magnolia and an extract of magnolia" may be a focus, particularly how it reads on a blended commercial ingredient like Relora®.
  • Technical Questions: As with the '384 patent, proving that the specific ingredient amounts in the accused product are "synergistically effective" will be a central evidentiary challenge for the plaintiff.

V. Key Claim Terms for Construction

• The Term: "synergistically effective" (asserted in both patents)

• Context and Importance: This functional language is central to the claims and the infringement theory. The dispute will likely focus on the standard of proof required to show that the effect of the combined ingredients is greater than the sum of their individual effects.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification provides a general definition: "synergy refers to the effect wherein a combination of two or more components provides a result which is greater than the sum of the effects produced by the agents when used alone" '384 Patent, col. 5:30-34 This definition is not tied to a specific quantitative threshold or measurement technique.
  • Evidence for a Narrower Interpretation: A defendant may argue that the term should be interpreted in light of the specific experimental data disclosed, such as the neurotransmitter level changes in mice or the behavioral test results in rats shown in the patent's examples '384 Patent, Figs. 1-7C '384 Patent, col. 9:1-12:65 This could support a narrower construction requiring a specific type or magnitude of synergistic effect.

• The Term: "whey protein" ('384 Patent, Claim 1)

• Context and Importance: Infringement of the '384 Patent hinges on whether the "dried whey" in the accused product falls within the scope of this term Compl. ¶33

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: Plaintiff may argue for the term's plain and ordinary meaning, which would encompass the protein constituent of "dried whey." The specification also mentions "whey protein concentrate," suggesting the inventors contemplated forms other than pure protein isolates '384 Patent, col. 3:5
  • Evidence for a Narrower Interpretation: The specification places significant emphasis on "alpha-lactalbumin" as a key component of the whey protein, detailing its neuro-protective and mood-enhancing properties '384 Patent, col. 6:21-57 While dependent claim 2 explicitly recites alpha-lactalbumin, a defendant could argue that the detailed description implicitly limits the scope of "whey protein" in claim 1 to compositions that contain and rely on the properties of alpha-lactalbumin.

VI. Other Allegations

• Indirect Infringement: The complaint alleges contributory infringement under 35 U.S.C. § 271(c), asserting that SynergyLabs manufactures and distributes the accused products, which are material to the inventions, have no substantial non-infringing uses, and are known to be especially adapted for infringement Compl. ¶59 Compl. ¶66
• Willful Infringement: The willfulness allegation is based on both pre- and post-suit knowledge. The complaint alleges constructive knowledge, arguing that SynergyLabs, as a contract manufacturer in the pet supplement space, knew or should have known of the asserted patents Compl. ¶50 It further alleges actual knowledge based on a pre-suit notice letter sent February 27, 2026 Compl. ¶43 The complaint also points to marketing for the accused product that explicitly references Plaintiff's own patented product, Solliquin®, as evidence of knowledge Compl. ¶51

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of definitional scope: can the term "whey protein," which is described in the '384 patent specification with emphasis on the specific functions of alpha-lactalbumin, be construed to cover the "dried whey" ingredient alleged to be in the accused product?
• A second central issue will be the interpretation and application of the functional limitation "synergistically effective." The case may turn on whether the plaintiff can prove, beyond the defendant's marketing language, that the specific combination of ingredients in the accused product produces a biological effect that is demonstrably greater than the sum of its parts.
• A key question for willfulness will concern knowledge and intent: what did SynergyLabs, as a contract manufacturer, know or what should it have known about the patents-in-suit, particularly given its client's alleged marketing strategy of equating the accused product to the patentee's commercial embodiment?